Voyager Therapeutics Stock Alpha and Beta Analysis
| VYGR Stock | USD 4.23 0.15 3.42% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Voyager Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Voyager Therapeutics over a specified time horizon. Remember, high Voyager Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Voyager Therapeutics' market risk premium analysis include:
Beta 1.05 | Alpha (0.69) | Risk 4.51 | Sharpe Ratio (0.06) | Expected Return (0.26) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Voyager |
Voyager Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Voyager Therapeutics market risk premium is the additional return an investor will receive from holding Voyager Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Voyager Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Voyager Therapeutics' performance over market.| α | -0.69 | β | 1.05 |
Voyager Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Voyager Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Voyager Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Voyager Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Voyager Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Voyager Therapeutics shares will generate the highest return on investment. By understating and applying Voyager Therapeutics stock market price indicators, traders can identify Voyager Therapeutics position entry and exit signals to maximize returns.
Voyager Therapeutics Return and Market Media
The median price of Voyager Therapeutics for the period between Tue, Nov 19, 2024 and Mon, Feb 17, 2025 is 5.67 with a coefficient of variation of 10.75. The daily time series for the period is distributed with a sample standard deviation of 0.62, arithmetic mean of 5.75, and mean deviation of 0.46. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Erste Asset Management GmbH Purchases Shares of 1,058,378 Voyager Therapeutics, Inc. - MarketBeat | 12/03/2024 |
2 | Institutional investors own a significant stake of 48 percent in Voyager Therapeutics, Inc. | 12/11/2024 |
3 | Should Weakness in Voyager Therapeutics, Inc.s Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials | 12/23/2024 |
4 | Jane Street Group LLC Cuts Holdings in Voyager Therapeutics, Inc. - MarketBeat | 01/06/2025 |
5 | Disposition of 1191 shares by Todd Carter of Voyager Therapeutics at 5.13 subject to Rule 16b-3 | 01/14/2025 |
6 | Is it a Good Idea to Invest in Stoke Therapeutics Stock Now - Yahoo Finance | 01/17/2025 |
7 | Disposition of 5000 shares by Todd Carter of Voyager Therapeutics at 2.85 subject to Rule 16b-3 | 01/24/2025 |
8 | On The My Stocks Page - Stock Traders Daily | 01/29/2025 |
9 | Neurogenetic Medicine Pioneer Voyager Sets Stage for Major Healthcare Conference Appearance - StockTitan | 02/06/2025 |
10 | Disposition of 4358 shares by Fahey Sandell Jacquelyn of Voyager Therapeutics at 4.45 subject to Rule 16b-3 | 02/11/2025 |
11 | Acquisition by Pfreundschuh Peter P. of 76000 shares of Voyager Therapeutics at 7.43 subject to Rule 16b-3 | 02/12/2025 |
About Voyager Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Voyager or other stocks. Alpha measures the amount that position in Voyager Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Graham Number | 6.47 | 19.5 | 22.42 | 23.17 | Receivables Turnover | 64.02 | 2.96 | 2.66 | 2.53 |
Voyager Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Voyager Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Voyager Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Voyager Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Voyager Therapeutics. Please utilize our Beneish M Score to check the likelihood of Voyager Therapeutics' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Voyager Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.